Clinical and Surgical Evaluations of Reoperation After Mechanical Mitral Valve Replacement Due to Different Etiologies

Jiehui Li, Shuiyun Wang*, Hansong Sun, Jianping Xu, Chao Dong, Min Song and Qibin Yu

State Key Laboratory of Cardiovascular Disease, Department of Cardiac Surgery, National Center for Cardiovascular Diseases, Peking Union Medical College, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China

Background: This study aimed to evaluate the clinical and surgical characteristics of patients who required reoperation after mechanical mitral valve replacement (MVR).

Methods: We retrospectively identified 204 consecutive patients who underwent reoperation after mechanical MVR between 2009 and 2018. Patients were categorized according to the reason for reoperation (perivalvular leakag e, thrombus formation, or pannus formation). The patients’ medical and surgical records were studied carefully and the rates of in-hospital complications were calculated.

Results: The mean age was 51±12 years and 44% of the patients were male. The reasons for reoperation were perivalvular leakage (117 patients), thrombus formation (35 patients), and pannus formation (52 patients). The most common positions for perivalvular leakage were at the 6–10 o’clock positions (proportions of ≥25% for each hour position). Most patients had an interval of >10 years between the original MVR and reoperation. The most common reoperation procedure was re-do MVR (157 patients), and 155 of these patients underwent concomitant cardiac procedures. There were 10 in-hospital deaths and 32 patients experienced complications. The 10-year survival rate was 82.2 ± 3.9% in general, and the group of lowest rate was patients with PVL (77.5 ± 5.2%). The independent risk factors were “male” (4.62, 95% CI 1.57–13.58, P = 0.005) and “Hb<9g/dL before redo MV operation” (3.45, 95% CI 1.13–10.49, P = 0.029).

Conclusion: Perivalvular leakage was the most common reason for reoperation after mechanical MVR, with a low survival rate in long term follow-up relatively.

Keywords: prosthesis malfunction, mitral valve replacement, perivalvular leakage, thrombus, pannus

INTRODUCTION

Mechanical prosthesis replacement is a valuable treatment option for mitral valve lesions. It offers a much longer life expectancy than a biological prosthesis. However, a few patients require secondary operation after mechanical mitral valve replacement (MVR). In such cases, the most common pathogeneses include perivalvular leakage (PVL), thrombus, or pannus formation. Although coupled with low prevalence (6.5% for 10 years follow-up, or 1,000–2,000 cases per year in Japan or the US), (1–4) the redo operation remains a significant challenge to clinicians and patients.
Several studies and reviews have examined the therapies and prognosis of redo operations after mechanical MVR, especially for patients with PVL (5–7). However, cases of thrombus or pannus were insufficient. In contrast, it was also worth comprehensively analyzing the operative techniques and their impacts on patients by different etiologies. Therefore, the current study aims to report the clinical features, operative techniques, and complications in-hospital of redo operations after mechanical MVR in our medical center.

MATERIALS AND METHODS

Patients Selection

More than 2,000 mitral valve surgeries have been completed in recent years in our hospital; however, only a few of these patients underwent secondary operations. This retrospective study evaluated patients undergoing reoperation after mechanical MVR from January 2009 to December 2018. Medical records, including echocardiographic, clinical, operative, and in-hospital outcomes, were collected. For inclusion, patients were also required to have undergone transthoracic Doppler echocardiography and preoperative coronary angiography if older than 45. The cause of redo MVR was attributed to perivalvular leakage, thrombogenesis, and pannus formation. Patients were categorized into groups correspondingly. For patients of PVL, because of the variances of mitral annular, a novel item, “summed points of PVL,” was used to evaluate the severity of perivalvular leakage, representing the overall points of a lesion by clock position. The medical records were reviewed carefully to confirm the cause of the operation. The details of lesions were affirmed by the surgery records in cases of inconsistencies with echocardiography or other imaging.

The primary endpoint was defined as the death in the follow-up. The secondary endpoint was defined as the complications in-hospital, including mortality in hospital, bleeding reoperation, continuous renal replacement therapy (CRRT), Intra-Aortic Balloon Pump (IABP), tracheotomy, stroke, ventilator usage ≥96 h, and ICU Stay ≥7 days.

Statistical Analysis

Continuous variables were expressed as mean ± standard deviation, and categoric variables were represented as percentages. Comparisons were performed by the χ² test or Fisher’s exact test for categorical variables and Student’s t-test.

| TABLE 1 | Preoperative characteristics of the study patients. |
|---------|---------------------------------------------------|
|         | PVL* (n = 117) | Thrombus (n = 35) | Pannus (n = 52) | Overall (n = 204) | P-value† |
| Age (y) | 51 ± 13        | 47 ± 13          | 52 ± 10        | 51 ± 12          | 0.10     |
| Male (%)| 69 (59%)       | 9 (26%)          | 11 (21%)       | 89 (44%)         | < 0.01   |
| BSA (m²)| 1.5 ± 0.4      | 1.2 ± 0.4        | 1.1 ± 0.3      | 1.3 ± 0.4        | < 0.01   |
| BMI (kg/m²)| 22 ± 3        | 23 ± 3          | 23 ± 4        | 22 ± 3          | 0.02     |
| Risk factors, n (%) |         |                 |               |                   |          |
| Atrial fibrillation**| 69 (59%)     | 21 (60%)        | 36 (69%)      | 126 (62%)       | 0.44     |
| Tricuspid regurgitation | 74 (63%)      | 16 (46%)        | 32 (62%)      | 122 (60%)       | 0.17     |
| Pulmonary hypertension | 45 (39%)      | 20 (57%)        | 25 (48%)      | 90 (44%)        | 0.12     |
| Hypertension | 17 (15%)      | 4 (11%)         | 3 (6%)        | 24 (12%)        | 0.26     |
| Diabetes mellitus | 6 (5%)        | 3 (9%)          | 3 (6%)        | 12 (6%)         | 0.75     |
| History of stroke | 6 (5%)        | 1 (3%)          | 10 (19%)      | 17 (8%)         | < 0.01   |
| NYHA III/IV | 69 (59%)      | 22 (63%)        | 29 (56%)      | 120 (59%)       | 0.80     |
| History of AVR | 42 (36%)      | 9 (28%)         | 12 (23%)      | 63 (31%)        | 0.19     |
| Echocardiology |                     |                 |               |                   |          |
| LVEF (%) | 60 ± 12        | 52 ± 22         | 56 ± 15       | 57 ± 15         | 0.07     |
| ≲50%, n (%) | 5 (4%)         | 1 (3%)          | 6 (12%)       | 12 (6%)         | 0.13     |
| LVEDD | 56 ± 13        | 40 ± 17         | 45 ± 11       | 53 ± 10         | < 0.01   |
| ≥55mm, n (%) | 74 (63%)      | 8 (23%)         | 11 (21%)      | 93 (46%)        | < 0.01   |
| MVPG§§ | 9 ± 5          | 14 ± 9          | 11 ± 6        | 10 ± 6          | < 0.01   |
| Hemoglobin (g/dL)| 118 ± 23       | 128 ± 21        | 120 ± 22      | 120 ± 23        | 0.08     |
| Intervals of operations (y) | 11 ± 8         | 9 ± 7           | 15 ± 8        | 12 ± 8         | < 0.01   |
| ≥10y, n (%) | 61 (52%)       | 19 (54%)        | 40 (77%)      | 120 (59%)       | 0.01     |

*PVL, Perivalvular Leakage.
†Comparisons among PVL, thrombus or pannus.
BSA, Body Surface Area.
BMI, Body Mass Index.
**Atrial fibrillation, Atrial fibrillation before redo MV operation.
††LVEF, Left Ventricular Ejection Fraction.
LVEDD, Left Ventricular End Diastolic Diameter.
§MVPG, Mitral Valve Pressure Gradient.
P value < 0.05 with significant difference in statistics.
for continuous variables. Multiple logistic regression models were used to assess associations with the in-hospital outcomes. As appropriate, survival rates were compared between groups, using the log-rank test or Breslow's test. Predictors or risk factors were analyzed by Cox regression. All variables were included in the univariate analysis. Those with a probability value of <0.1 were included in the multivariate regression. In terms of the Cox multivariate model, missing values were replaced by multiple imputation, and predictor selection using backward stepwise regression with Akaike information criterion (AIC) was performed on all imputed datasets. All statistical tests were two-sided, and a probability value of <0.05 was considered statistically significant. Statistical analysis was performed using IBM SPSS software (version 19.0; IBM Corp., Armonk, NY, USA).

RESULTS
Characteristics of Patients With Redo Operations After Mechanical MVR
Two hundred and four patients underwent redo operation after mechanical MVR. Their average height was 1.64 ± 0.1 m, and average weight was 61 ± 11 kg, average age was 51 ± 12 years old, and 50 patients (24.5%) were older than 60. Groups were categorized by etiologies: perivalvular leakage \( (n = 117) \), thrombus \( (n = 35) \), and pannus \( (n = 52) \). The baseline and clinical data of patients enrolled are summarized in Table 1.

Most baseline characteristics among the patients showed no difference in statistical terms. Patients with perivalvular leakage had more proportion of males \( (n = 69, 59\%) \), with the highest BSA \( (1.5 ± 0.4 \text{ m}^2) \) and the lowest BMI \( (22 ± 3 \text{ kg/m}^2) \). The pannus group had the longest interval of operations \( (15 ± 8 \text{ years, } p = 0.001) \). Group PVL had the largest left ventricular end-diastolic diameter \( (\text{LVEDD}, 56 ± 13 \text{ mm, } p < 0.001) \), and group thrombus had the greatest mitral valve pressure gradient \( (\text{MVPG}, 14 ± 9 \text{ mmHg, } p = 0.004) \).

As displayed in Figure 1, more than half of the patients had more than 10 years gap between operations. Especially for patients with pannus, the average interval was 15 ± 8 years, and few of them underwent redo operations <10 years after primary surgery. The majority of PVL patients were in the group “< 2 years” \( (n = 27, 84.4\%) \). Moreover, among patients with thrombus, the morbidity of redo surgery appeared to be similar in the entire cohort.
Detailed documentation of perivalvular leakage was available for 109 (93% of PVL group). Figure 2 illustrates the distribution of perivalvular leakage illustrated by the clock position on a radar chart. Eighty-one patients (74% of PVL records) had more than one point of lesion. The most susceptible regions appeared from six to ten o’clock, with a prevalence of no <25%.

We used a novel item, “summed points of PVL,” to evaluate the severity of perivalvular leakage, representing the lesion’s overall points by clock position. Generally, patients were found to have 2.6 ± 1.4 points (Figure 3), and it had no relationship with the interval of operations (r = 0.06, p = 0.56). Furthermore, we analyzed the PVL patients combined with AVR simultaneously and found no relationship between “summed points of PVL” and “aortic valve replacement” (eight of one point, eight of two summed points, and seven of more than two points, p = 0.797).

Characteristics of Redo Operations After Mechanical MVR
One hundred and fifty-seven patients underwent repeat MVR, with 147 mechanical prostheses (94% of re-MVR) implanted. Forty patients of perivalvular leakage (34% of PVL group) underwent PVL repair, and seven patients (14% of pannus group) underwent pannus clearance only.
One hundred and fifty-five patients underwent concomitant heart procedures, including 131 tricuspid valve repairs and 54 aortic valve replacements (AVR) (Table 2). The operation time was $327 \pm 104$ min, and the aortic cross-clamping (ACC) time was $103 \pm 79$ min. Operations in the PVL group had a shorter ACC time than non-PVL groups (min: $96 \pm 46: 112 \pm 50, p = 0.01$). We had recorded 10 deaths (mortality of 4.9%) in the hospital. And as shown in Table 3, there was no difference among the three groups in terms of complications in general or in detail.

Follow-Up of Redo Operations After Mechanical MVR

The overall survival rate at 10 years was 82.2 ± 3.9%. As shown in Figure 4, there was no difference among the three groups in terms of etiologies (log-rank test, $P = 0.18$). However, differences could be observed after categorizing patients into the PVL group and Others group (non-PVL group) (log-rank test, $P = 0.06$). Univariate and multivariate Cox regression analyses (Table 4) revealed that “Male” (4.62, 95% CI 1.57–13.58, $P = 0.005$) and “Hb < 9g/dL before secondary MV operation” (3.45, 95% CI 1.13–10.49, $P = 0.029$) were the independent risk factors in patients undergoing redo operations after mechanical MVR. Additionally, LVEF might influence the late outcomes of patients after the redo MV operation (1.07, 95% CI 1–1.14, $P = 0.061$).

DISCUSSION

Patients by Different Etiologies of Redo Operations After Mechanical MVR

In the present study, perivalvular leakage was the most important pathogenesis leading to a secondary operation after mechanical MVR. Patients with perivalvular leakage had a longer diameter of left ventricular end-diastole, and the percentage of left ventricular dilation ($LVEDD \geq 55$ mm) was up to 63%. This could be attributed to the fact that the pathophysiology was similar to mitral regurgitation, which also led to a shorter interval between operations than patients with pannus or thrombus (years: $11 \pm 8: 13 \pm 8, p = 0.058$). These findings were in line with Botta et al. report (mean: 130 months) (9). Most studies proposed that patients require intervention only with the moderate-severe PVL or coupled with symptoms; mild PVL without symptoms usually had a benign course and could be managed in follow-up carefully (10). However, the surgeries peaked slightly in PVL patients during the first 2 years. This spike in the extremely short interval might be attributed to the surgical techniques being used. Meanwhile, patient numbers in other groups increased gradually with time in 10 years, after former mechanical MVR from our study.

In the current investigation, the perivalvular leakage in the mitral position was predominantly at six to ten o’clock position ($\geq 25%$ in each point), which was mirror-symmetric to Bouhout et al. study (from two to six o’clock, $\geq 35%$ for each point) (6). Meanwhile, another important assessment was the severity of PVL. Because of the different sizes of mitral prostheses, it might be unreasonable to compare them by length or width directly. We analyzed the item, “summed points of PVL” (2.6 ± 1.4 points), which represented the overall leakage points by clock position. These data could benefit further analysis.

Patients with pannus had the greatest MVPG in the cohort (14 ± 9 mmHg, $p = 0.004$). This was in line with previous studies and reports on pannus and thrombus (11, 12). The current consensus showed that pannus always formed as a circular mass curved along the ring, and thrombus tended to infest into the prosthesis,
TABLE 2 | Blood transfusion and operative characteristics of the study patients.

|                   | PVL*** (n = 117) | Thrombus (n = 35) | Pannus (n = 52) | Overall (n = 204) | P-value†††† |
|-------------------|------------------|------------------|----------------|-------------------|-------------|
| Operative techniques |                  |                  |                |                   |             |
| PVL-repairing     | 40 (34%)         | -                | -              | 40 (20%)          | -           |
| Pannus clearance  | -                | -                | 7 (14%)        | 7 (3%)            | -           |
| Mitral valve replacement | 77 (66%) | 35 (100%) | 45 (87%) | 157 (77%) | <0.01 |
| Mechanical prosthesis | 76  | 30  | 41  | 147  | 0.02 |
| Size of prosthesis (mm) | 27 ± 2 | 26 ± 1 | 26 ± 1 | 26 ± 2 | <0.01 |
| Concomitant procedure, n*** | 87 (74%) | 24 (69%) | 44 (85%) | 155 (76%) | 0.19 |
| Aortic valve replacement | 26 (22%) | 7 (20%) | 21 (40%) | 54 (27%) | 0.03 |
| Tricuspid valve repairing | 76 (65%) | 20 (57%) | 35 (67%) | 131 (64%) | 0.61 |
| Operation time (mins) | 330 ± 107 | 321 ± 114 | 325 ± 98 | 327 ± 104 | 0.93 |
| CPB time†††† | 157 ± 71 | 105 ± 45 | 117 ± 53 | 103 ± 48 | 0.02 |
| ACC time | 96 ± 46 | 105 ± 45 | 117 ± 53 | 103 ± 48 | 0.02 |
| P-ACC time*** | 30 ± 22 | 33 ± 30 | 40 ± 52 | 33 ± 34 | 0.89 |
| P-ACC: ACC | 0.36 ± 0.27 | 0.34 ± 0.29 | 0.36 ± 0.38 | 0.35 ± 0.30 | 0.33 |
| Length of hospital stay (d) | 26 ± 18 | 15 ± 7 | 18 ± 10 | 22 ± 15 | <0.01 |
| Postoperative stay (d) | 13 ± 11 | 11 ± 6 | 10 ± 6 | 12 ± 9 | 0.08 |
| ICU stay (h) | 101 ± 147 | 94 ± 116 | 83 ± 99 | 95 ± 131 | 0.76 |
| Ventilator usage (h) | 48 ± 67 | 48 ± 76 | 37 ± 39 | 45 ± 75 | 0.38 |
| Blood Transfusion |                  |                  |                |                   |             |
| Red blood cell (u) | 8 ± 7 | 9 ± 14 | 6 ± 5 | 8 ± 8 | 0.49 |
| Plasma (ml) | 917 ± 780 | 1,216 ± 2,229 | 741 ± 572 | 939 ± 1,163 | 0.63 |
| Platelet (u) | 1.6 ± 1.5 | 1.5 ± 0.8 | 1.5 ± 1.6 | 2.0 ± 3.5 | 0.89 |

*** PVL, Perivalvular Leakage.
†††† Comparisons among PVL, thrombus or pannus.
Values are n (%), or median (interquartile range).
*** Comparisons (PVL, Thrombus, & Pannus) in patients received redo MVR replacement.
* No. of patients received concomitant procedures.
†††† CPB, Cardio-Pulmonary Bypass.
ACC, Aortic Cross Clamping.
*** P-ACC, CPB time of Post ACC.
P value < 0.05, with significant difference in statistics.

which further restricted leaflet motion and caused a malfunction. Moreover, patients with pannus had the most prolonged interval of operations (15 ± 8 years, p = 0.001). The development of pannus that can affect the hemodynamics of artificial prostheses requires a significant amount of time (13). In contrast, thrombi always give rise to acute symptoms, leading to shorter intervals (9 ± 7 years), similar to our study. These findings were consistent with Sepharham et al. report (14).

Techniques and Details of Redo Operations
Thirty-three percent of PVL patients underwent perivalvular leakage repair, with shorter aortic cross-clamping time than redo MVR in the same group (min: 78 ± 45: 105 ± 44, p = 0.002). However, this procedure did not cut down the operation time and Cardio-Pulmonary Bypass (CPB) time in general. Moreover, CPB time after ACC was not significantly different between the three etiologic groups. Thus, it could be recognized that the operative techniques would not impact the difficulty of surgery.

The most common type of operative technique was the repeated replacement of mitral prosthesis (re-MVR), received by 66% of patients of PVL in our cohort. However, Bouhout et al. study showed that 76% of patients underwent PVL repair, who also reported the opposite distribution of PVL points mentioned above (6). PVL patients also had a larger prosthesis size than patients with thrombus or pannus in our hospital. All re-MVRs implanted artifacts had a size similar to the previous operation. The mechanical prosthesis was the mainstream choice for surgeons, even for patients aged more than 65 years. There were 11 cases of 14 implantations (three bioprosthetic valves). For these cases, there were four with small aortic annulus (size 19 or 21), two with endocarditis, one with Behcet’s disease, and one with patient preference. These results might differ from Fukunaga et al. findings, which suggested that 75% of patients aged 50–69 years had received biological prostheses (15). However, the composition of their cohort was significantly different from ours, as there were only 6.8% cases of PVL in the mechanical MVR group.

Among patients undergoing concomitant operations, 22% (54 patients) had AVR, of which 31 patients underwent secondary replacement. The most common lesion of the aortic prosthesis was pannus formation (n = 16), and there were eight patients with a mean aortic valve pressure gradient >30 mmHg at rest. In our cohort, secondary AVR was more common among patients with a history of AVR [OR 3.54, 95%CI (1.84, 6.81), p < 0.01].

Meanwhile, in the present study, there were seven patients who underwent pannus removal through the transaortic route.
TABLE 3 | Complications of redo operations after mechanical MVR.

| Complications                  | PVL (n = 117) | Thrombus (n = 35) | Pannus (n = 52) | Overall (n = 204) | P-value |
|--------------------------------|---------------|-------------------|----------------|-------------------|---------|
| PVL†                           | 19 (16%)      | 6 (17%)           | 7 (13%)        | 32 (16%)          | 0.87    |
| ICU stay ≥ 7d                  | 12 (10%)      | 3 (9%)            | 2 (4%)         | 17 (8%)           | 0.38    |
| Ventilator usage ≥ 96 h        | 7 (6%)        | 3 (9%)            | 4 (8%)         | 14 (7%)           | 0.84    |
| Mortality in hospital          | 4 (3%)        | 3 (9%)            | 3 (6%)         | 10 (5%)           | 0.44    |
| CRRT**                         | 8 (7%)        | 3 (9%)            | 1 (2%)         | 12 (6%)           | 0.35    |
| Trachectomy                    | 5 (4%)        | 1 (3%)            | 1 (2%)         | 7 (3%)            | 0.73    |
| Bleeding reoperation           | 5 (4%)        | 2 (6%)            | 4 (8%)         | 11 (5%)           | 0.66    |

*Complications: mortality in hospital, bleeding reoperation, CRRT, IABP, tracheotomy, stroke, ventilator usage ≥ 96 h, ICU Stay ≥ 7 d; †PVL, Perivalvular Leakage. Comparisons among PVL, thrombus or pannus. §No. of patients with complications after redo MV operation. **CRRT, Continuous Renal Replacement Therapy.

TABLE 4 | Univariate/multivariate cox regression of redo operations after mechanical MVR.

| Variables                  | Univariate regression HR (95% CI) | P-value | Multivariate regression HR (95% CI) | P-value |
|----------------------------|-----------------------------------|---------|-------------------------------------|---------|
| Age                        | 1.02 (0.98, 1.06)                 | 0.256   | 4.62 (1.57, 13.58)                  | 0.005   |
| Male                       | 4.62 (1.69, 12.63)                | 0.003   | 4.62 (1.57, 13.58)                  | 0.005   |
| BMI                        | 1.02 (0.90, 1.16)                 | 0.728   | 0.84 (0.41, 1.76)                   | 0.649   |
| Etiologies                 | 0.54 (0.26, 1.11)                 | 0.093   | 0.457                               |         |
| NYHA III/IV                | 1.41 (0.57, 3.50)                 | 0.457   |                                     |         |
| PH                         | 0.91 (0.38, 2.20)                 | 0.839   |                                     |         |
| Atrial fibrillation        | 1.19 (0.48, 2.94)                 | 0.712   |                                     |         |
| Hb<9g/dL                   | 3.67 (1.22, 11.06)                | 0.021   | 3.45 (1.13, 10.49)                  | 0.029   |
| MVRS                       | 0.86 (0.24, 1.49)                 | 0.269   |                                     |         |
| Multi-Operation            | 3.12 (0.73, 13.38)                | 0.126   |                                     |         |
| LVEDDxxi                   | 1.01 (0.97, 1.05)                 | 0.770   |                                     |         |
| LVEFxii                    | 1.06 (1, 1.13)                    | 0.063   | 1.07 (1, 1.14)                      | 0.061   |

xxiiiBMI, Body Mass Index.
xxivEtiologies, PVL, thrombus, pannus.
xxvPH, Pulmonary Hypertension.
xxviAtrial fibrillation, Atrial fibrillation before redo MV operation.
xxviiMVRS, Patients receiving MVR finally during the redo MV operation.
xxviiiMulti-Operation, Multi-cardiac operations performed simultaneously during the redo MV operation.
xxixLVEDD, Left Ventricular End Diastolic Diameter.
xxxLVF, Left Ventricular Flection.

Their MVPG was 5 ± 1 mmHg, compared to 11 ± 7 mmHg (p = 0.001). Park et al. (16) found that patients with MVPG <5 mmHg could not benefit from the pannus clearance. Our findings were in line with their report.

Endpoints After Redo Operations

Complications during the perioperative period have already been outlined in the Results section. The in-hospital mortality in our cohort was relatively low in our study compared to previous reports (2, 7, 17). The prevalence of diabetes and postoperative stroke (one case) was at an extremely low level, (18, 19) and the morbidity of bleeding during reoperation in our study was similar to a previous study (20). However, the ICU stay time and length of hospital stay after the operation was longer in our study than that reported earlier (19).

The overall survival rate at 10 years for our study participants was 82.2 ± 3.9%, similar to that reported by Fukunaga et al. (survival rate: 79.2%) (21). In our study cohorts, the PVL group had an outcome of 77.5 ± 5.2% after a 10-year follow-up which was the worst among the three groups. This might be due to the larger LVEDD than other groups (percentage of LVEDD > 65 mm; PVL: Thrombus: Pannus; 63: 23: 21%). Patients with PVL always had worse outcomes than those patients with thrombus or pannus (1, 7, 14, 21). However, the survival rate of PVL patients in our study was still higher than in some studies, such as Bouhout et al. (57 ± 6%) (6). This may be attributed to the inclusion of relatively older adults in their group and a higher proportion of patients with NYHA III/IV. Furthermore, Botta et al. reported a survival rate at 5 years similar to our study (88.8: 84.0%) (9). However, these studies had different outcomes after
Cox regression analysis. Our research had found that “male” and “Hb <9g/dL before secondary MV operation” were independent risk factors affecting long-term prognosis.

Patients with thrombus in our study had a 10 years survival rate of 91.8 ± 5.5%, which was mildly lower than that reported by Raman et al. (97.4 ± 1.2%) (22). Furthermore, those with pannus had a moderate survival rate (89.5%) compared with the thrombus group and PVL group, similar to findings reported by Park et al. (87.6%) (23). This suggests that patients with mechanical mitral valve dysfunction would have a good prognosis if they underwent a proper redo procedure.

Limitations of the Study
There were some limitations to our study. First, due to insufficient or missing clinical data, the insights drawn based on the surgical and patient history might not be fully valid and acceptable. Many patients did not undergo echocardiography in recent 2–3 years, making it further challenging to analyze the functioning of mechanical prostheses.

CONCLUSION
Despite the low prevalence, reoperation after mechanical mitral valve replacement remains a key challenge. In our study, perivalvular leakage might be the possible cause of operation, which might lead to a low survival rate in the long-term follow-up relatively. Male patients with low hemoglobin (Hb <9g/dL) before the redo MV operation might have a worse outcome during the long-term follow-up compared to other patient subgroups.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article-supplementary material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the Ethics Committee of Fuwai Hospital, National Center for Cardiovascular Disease. The Ethics Committee waived the requirement of written informed consent for participation.

AUTHOR CONTRIBUTIONS
SW, HS, JX, and CD: main surgeons of operations. JL, MS, and QY: statistics. JL and SW: writing. SW: general responsibility. All authors contributed to the article and approved the submitted version.

REFERENCES
1. Nishida T, Sonoda H, Oishi Y, Tanoue Y, Nakashima A, Shiokawa Y, et al. Single-institution, 22-year follow-up of 786 carbomedics mechanical valves used for both primary surgery and reoperation. J Thorac Cardiovasc Surg. (2014) 147:1493–8. doi: 10.1016/j.jtcvs.2013.05.017
2. Furukawa H, Tanemoto K. Redo valve surgery—current status and future perspectives. Ann Thorac Cardiovasc Surg. (2014) 20:267–75. doi: 10.5761/atcs.ra.13-00380
3. Tanemoto K, Furukawa H. Repeated valve replacement surgery: technical tips and pitfalls. Gen Thorac Cardiovasc Surg. (2014) 62:639–44. doi: 10.1007/s11748-014-0473-z
4. Kilic A, Acker MA, Gleason TG, Sultan I, Vemulapalli S, Thibault D, et al. Clinical outcomes of mitral valve reoperations in the United States: an analysis of the society of thoracic surgeons national database. *Ann Thorac Surg.* (2019) 107:754–9. doi: 10.1016/j.athoracsur.2018.08.083

5. Rodriguez Muñoz D, Lázaro Rivera C, Zamorano Gómez JL. Guidance of treatment of perivalvular prosthetic leaks. *Curr Cardiol Rep.* (2014) 16:430. doi: 10.1007/s11886-013-0430-y

6. Bouhout I, Mazine A, Ghoneim A, Millàn X, El-Hamamsy I, Pellerin M, et al. Long-term results after surgical treatment of paravalvular leak in the aortic and mitral position. *J Thorac Cardiovasc Surg.* (2016) 151:1260–6.e1. doi: 10.1016/j.jtcvs.2015.11.046

7. Taramasso M, Maisano F, Denti P, Guidotti A, Sticchi A, Pozzoli A, et al. Surgical treatment of paravalvular leak: long-term results in a single-center experience (up to 14 years). *J Thorac Cardiovasc Surg.* (2015) 149:1270–5. doi: 10.1016/j.jtcvs.2014.12.041

8. https://www.fuwaihospital.org/News/Columns/List/810

9. Botta L, De Chiara B, Quattrocchi S, Casadei F, Borgia F, Giannattasio E, et al. Mitral periprosthetic leakage: contemporary results of surgical correction at a single centre. *Interact Cardiovasc Thorac Surg.* (2017) 25:185–90. doi: 10.1093/icvts/ivx101

10. Giblett JP, Rana BS, Shapiro LM, Calvert PA. Percutaneous management of paravalvular leaks. *Nat Rev Cardiol.* (2019) 16:275–85. doi: 10.1038/s41569-018-0147-0

11. Gürsoy MO, Kalçik M, Karakoyun S, Özkan M. The current status of fluoroscopy and echocardiography in the diagnosis of prosthetic valve thrombosis-a review article. *Echocardiography.* (2015) 32:156–64. doi: 10.1111/echo.12721

12. Tanis W, Habets J, van den Brink RB, Symersky P, Chamuleau SA. Differentiation of thrombus from pannus as the cause of acquired mechanical prosthetic heart valve obstruction by non-invasive imaging: a review of the literature. *Eur Heart J Cardiovasc Imaging.* (2014) 15:119–29. doi: 10.1093/ehjci/jet127

13. Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R. Prosthetic heart valve thrombosis. *J Am Coll Cardiol.* (2016) 68:2670–89. doi: 10.1016/j.jacc.2016.09.958

14. Sepharham A, Ghaffari S, Aslanabadi N, Sohrabi B, Ghojazadeh M, Anamzadeh E, et al. Prosthetic valve thrombosis. *J Card Surg.* (2015) 30:246–50. doi: 10.1111/jocs.12510

15. Fukunaga N, Miyakoshi C, Sakata R, Koyama T. Impact of valve type on outcomes after redo mitral valve replacement in patients aged 50 to 69 years. *Interact Cardiovasc Thorac Surg.* (2018) 27:322–7. doi: 10.1093/icvts/ivy109

16. Park B, Sung K, Park PW. Clinical implication of transaortic mitral pannus removal during repeat cardiac surgery for patients with mechanical mitral valve. *Circ J.* (2018) 82:396–402. doi: 10.1253/circj.CJ-17-0463

17. Huang G, Schaff HV, Sundt TM, Rahimtoola SH. Treatment of obstructive thrombosed prosthetic heart valve. *J Am Coll Cardiol.* (2013) 62:1731–6. doi: 10.1016/j.jacc.2013.07.075

18. Said SM, Schaff HV, Greason KL, Pochettino A, Daly RC, Dearani JA. Reoperation for mitral paravalvular leak: a single-centre experience with 200 patients. *Interact Cardiovasc Thorac Surg.* (2017) 25:806–12. doi: 10.1093/icvts/ivy222

19. Mehaffey HJ, Hawkins RB, Schubert S, Fonner C, Yarboro LT, Quader M, et al. Contemporary outcomes in reoperative mitral valve surgery. *Heart.* (2018) 104:652–6. doi: 10.1136/heartjnl-2017-312047

20. Hwang HY, Choi JW, Kim HK, Kim KH, Kim KB, Ahn H. Paravalvular leak after mitral valve replacement: 20-year follow-up. *Ann Thorac Surg.* (2015) 100:1347–52. doi: 10.1016/j.athoracsur.2015.03.104

21. Fukunaga N, Sakata R, Koyama T. Short- and long-term outcomes following redo valvular surgery. *J Card Surg.* (2018) 33:56–63. doi: 10.1111/jocs.13534

22. Raman K, Mohanraj A, Palanisamy V, Ganesh J, Rawal S, Kurian VM, et al. Thrombolysis and surgery for mitral prosthetic valve thrombosis: 11-year outcomes. *Asian Cardiovasc Thorac Ann.* (2019) 27:633–40. doi: 10.1177/0218492319878015

23. Park PW, Park B, Jeong DS, Sung K, Kim WS, Lee YT, et al. Clinical outcomes of repeat aortic valve replacement for subaortic pannus in mechanical aortic valve. *Circ J.* (2018) 82:2535–41. doi: 10.1253/circj.CJ-18-0352

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Li, Wang, Sun, Xu, Dong, Song and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.